Market Place
Sourcing Support
Reviva Reports Q3 2024 Financial Results & Business Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Reviva to Present Brilaroxazine Speech Data at CNS Summit 2024
06 Nov 2024 //
GLOBENEWSWIRE
Reviva to Participate in the UBS Global Healthcare Conference
31 Oct 2024 //
GLOBENEWSWIRE
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
08 Oct 2024 //
GLOBENEWSWIRE
Reviva Joins 3rd Annual ROTH Healthcare Conference
02 Oct 2024 //
GLOBENEWSWIRE
Reviva Pharmaceuticals To Participate In Lytham Conference
26 Sep 2024 //
GLOBENEWSWIRE
Reviva Announces New Vocal Biomarker Data
09 Sep 2024 //
GLOBENEWSWIRE
Reviva To Join H.C. Wainwright Investment Conference
04 Sep 2024 //
GLOBENEWSWIRE
Reviva To Host KOL Event On Brilaroxazine Vocal Biomarker Data
27 Aug 2024 //
GLOBENEWSWIRE
Reviva Pharmaceuticals Prices $5M At-Market Offering
21 Aug 2024 //
GLOBENEWSWIRE
Reviva Reports Q2 2024 Financial Results And Business Highlights
14 Aug 2024 //
GLOBENEWSWIRE
Reviva Gets US Patent For Brilaroxazine In Pulmonary Fibrosis
06 Aug 2024 //
GLOBENEWSWIRE
Reviva Gets European Patent For Brilaroxazine In Pulmonary Hypertension
09 Jul 2024 //
GLOBENEWSWIRE
Reviva Closes $3M Direct Offering Per Nasdaq Rules
29 May 2024 //
GLOBENEWSWIRE
Reviva: $3M Direct Offering Priced Per Nasdaq Rules
28 May 2024 //
GLOBENEWSWIRE
Reviva to Participate in the BIO International Convention
21 May 2024 //
GLOBENEWSWIRE
Reviva Provides Enrollment Update For Brilaroxazine
15 May 2024 //
GLOBENEWSWIRE
Reviva Reports Q1 2024 Results, Business Highlights
14 May 2024 //
GLOBENEWSWIRE
Reviva To Present Brilaroxazine Efficacy Data In IPF At ATS 2024
13 May 2024 //
GLOBENEWSWIRE
Reviva Brilaroxazine Preclinical Data At ASPET 2024
09 May 2024 //
GLOBENEWSWIRE
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15 Apr 2024 //
GLOBENEWSWIRE
Reviva to Present Ph 3 Data for Brilaroxazine in Schizophrenia at the Meeting
28 Mar 2024 //
GLOBENEWSWIRE
Reviva to Present Ph 3 Data for Brilaroxazine in Schizophrenia at Meeting
26 Mar 2024 //
GLOBENEWSWIRE
Reviva to Present at the UBS Virtual CNS Day
11 Mar 2024 //
GLOBENEWSWIRE
Reviva to Present at the 36th Annual ROTH Conference
07 Mar 2024 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
20 Feb 2024 //
GLOBENEWSWIRE
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 of Brilaroxazine
06 Feb 2024 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Participate in a Fireside Chat
25 Jan 2024 //
GLOBENEWSWIRE
Reviva Provides Corporate and Program Updates and Highlights Key Milestones
04 Jan 2024 //
GLOBENEWSWIRE
Reviva to Participate in Zacks Small-Cap Research Life Sciences Investor Forum
11 Dec 2023 //
GLOBENEWSWIRE
Reviva Pharma to Participate in The Benchmark Company™s Investor Conference
30 Nov 2023 //
GLOBENEWSWIRE
Reviva Announces Closing of $30 Million Registered Direct Offering
20 Nov 2023 //
GLOBENEWSWIRE
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market
16 Nov 2023 //
GLOBENEWSWIRE
Reviva Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Reviva Pharma`s schizophrenia drug succeeds in late-stage study
31 Oct 2023 //
HEALTH ET
Reviva Announces Last Patient Evaluated in Phase 3 Trial for Brilaroxazine
25 Sep 2023 //
GLOBENEWSWIRE
Reviva to Participate in H.C. Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Reviva Announces Enrollment Completion for Phase 3 Study for Brilaroxazine
17 Aug 2023 //
GLOBENEWSWIRE
Reviva Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
31 Jul 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to be Added to Russell Microcap® Index
26 Jun 2023 //
GLOBENEWSWIRE
Reviva Announces 80% Global Enrollment for Pivotal Ph3 RECOVER Brilaroxazine
22 Jun 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at Upcog Investor Conferences in June
15 Jun 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine
25 May 2023 //
GLOBENEWSWIRE
Reviva Announces Presentation of Data on Brilaroxazine at the ASPET
22 May 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform
19 May 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023
18 May 2023 //
GLOBENEWSWIRE
Reviva Reports 1Q 2023 FYR Results and Recent Business Highlights
15 May 2023 //
GLOBENEWSWIRE
Reviva to Participate in the Lytham Partners Spring 2023 Investor Conference
12 May 2023 //
GLOBENEWSWIRE
Reviva Announces Intent to File an IND for Brilaroxazine in Psoriasis
11 May 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at Three Upcoming Conferences in May 2023
04 May 2023 //
GLOBENEWSWIRE
Reviva Presented Preclinical Data on Novel Serotonin-Dopamine Brilaroxazine
01 May 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine
25 Apr 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Brilaroxazine
20 Apr 2023 //
GLOBENEWSWIRE
Reviva Reports Full Year 2022 Financial Results and Business Highlights
30 Mar 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference
07 Mar 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference
31 Jan 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals Announces Letter to Shareholders
04 Jan 2023 //
GLOBENEWSWIRE
Reviva Pharma Announces Positive Safety Data from Study of Brilaroxazine
15 Dec 2022 //
GLOBENEWSWIRE
Reviva Announces Canadian Composition of Matter Patent for Inhibitor RP1208
21 Nov 2022 //
GLOBENEWSWIRE
